Gilead will acquire Calistoga and CAL101

[Guest guest]

Calistoga has a portfolio of proprietary compounds that selectively target

isoforms of phosphoinositide-3 kinase (PI3K). This pathway has been shown to be

a central signaling pathway for cellular proliferation, survival and

trafficking.

Calistoga's lead product candidate, CAL-101, is a first-in-class specific

inhibitor of the PI3K delta isoform.

Gilead Sciences is a biopharmaceutical company that discovers, develops and

commercializes innovative therapeutics in areas of unmet medical need.

Press Release:

http://www.calistogapharma.com/pdf/Calistoga2.22.11.pdf

~chris